Anti-LY75 Antibody and Platinum Drug Combination for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly those involving platinum-based drugs, face challenges such as drug resistance, severe side effects, and the need for new efficacious combination therapies.
Innovation Solution
The development of a pharmaceutical combination comprising anti-LY75 antibodies or antigen-binding portions thereof, in conjunction with platinum-based antineoplastic drugs, demonstrating synergistic results in treating cancers mediated by LY75 expression or activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based drugs (cisplatin, carboplatin, oxaliplatin) are used for cancer treatment, then therapeutic efficacy is improved, but drug resistance develops and severe side effects occur
Solution Approach 1:
The patent combines anti-LY75 antibodies with platinum-based drugs to create a combination therapy that synergistically enhances anticancer efficacy while overcoming drug resistance. The antibody targets LY75-expressing cancer cells specifically, and when combined with platinum drugs, achieves greater therapeutic effect than either agent alone, thereby improving reliability while mitigating the development of resistance
Solution Approach 2:
The anti-LY75 antibody provides localized targeting to cancer cells that express the LY75 antigen, concentrating the therapeutic effect at the tumor site. This localized action enhances efficacy at the target while reducing systemic exposure and thereby decreasing severe side effects such as kidney problems, hearing loss, and gastrointestinal disorders
2Reliability
If cisplatin is used at high doses to overcome resistance, then therapeutic efficacy is improved, but toxicity increases significantly
Solution Approach 1:
The combination of anti-LY75 antibodies with platinum-based drugs creates a synergistic effect that allows for enhanced therapeutic efficacy at lower doses of the platinum drug. The antibody component contributes to the anticancer activity, enabling dose reduction of the toxic platinum agent while maintaining or improving overall efficacy
Solution Approach 2:
The anti-LY75 antibody acts as an intermediary that enhances the anticancer effect of platinum drugs through targeted delivery and synergistic mechanism. The antibody binds to LY75 on cancer cells and facilitates the therapeutic action, allowing the platinum drug to work more efficiently at lower concentrations, thereby reducing toxicity
3Reliability
If combination chemotherapy with multiple drugs is used, then resistance development is minimized, but treatment complexity increases
Solution Approach 1:
The patent combines two distinct therapeutic agents with different mechanisms of action: anti-LY75 antibodies that target cancer cells expressing the LY75 antigen and platinum-based drugs that damage DNA. This combination minimizes resistance development through mechanism diversity while maintaining relatively simple treatment protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy shows promise in overcoming drug resistance and reducing side effects, achieving enhanced therapeutic efficacy in treating various cancers by specifically targeting LY75-expressing cancer cells.
Implementation Method 1
Lymphocyte antigen 75 acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment
Implementation Method 2
Cisplatin is taken into cells and reacts with intracellular macromolecules to form protein, RNA, and DNA adducts
Data Source
AI summary
The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising antibodies, or antigen-binding portions thereof, directed against LY75, and a platin; methods for preparing pharmaceutical combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.